Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIBEC: Tislelizumab + Bevacizumab + Capecitabine in Advanced Solid Tumors
NCT07681297Phase 2Not yet recruiting
- Sponsor
- National University Hospital
- Start
- Aug 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in solid tumor, triple-negative breast cancer (TNBC), breast cancer, central nervous system disease, sponsored by National University Hospital. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
solid tumortriple-negative breast cancer (TNBC)breast cancercentral nervous system disease
Beyond the preview
Go deeper on NCT07681297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07681297.